Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government’s National Research Foundation (NRF).
The ClearCell® FX1 System by Clearbridge BioMedics provide a label-free means of Circulating Tumour Cell (CTC) enrichment that offers a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.